Morinidazole

Morinidazole is an orally active and 5-nitroimidazole antimicrobial agent that undergoes extensive metabolism in humans via N+-glucuronidation and sulfation. Morinidazole can be used for bacterial infections research including appendicitis and pelvic inflammatory disease (PID) caused by anaerobic bacteria[1].

Product Specifications

CAS Number

[92478-27-8]

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Morinidazole.html

Purity

98.0

Solubility

DMSO : ≥ 100 mg/mL

Smiles

OC(CN1C([N+]([O-])=O)=CN=C1C)CN2CCOCC2

Molecular Formula

C11H18N4O4

Molecular Weight

270.29

Precautions

H302, H312, H332

References & Citations

[1]Zhong K, et al. Effects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearanceof the conjugated metabolites. Antimicrob Agents Chemother. 2014 Jul;58 (7) :4153-61.|[2]Lu Aifeng, et al. Application of α- (morpholine-1-yl) methyl-2-methyl-nitroimidazole-1-ethanol as anti-trichomonal agent and amebacide: China, CN1981764[P]. 2007-06-20.|[3]Kong F, et al. Increased Plasma Exposures of Conjugated Metabolites of Morinidazole in Renal Failure Patients: A Critical Role of Uremic Toxins. Drug Metab Dispos. 2017 Jun;45 (6) :593-603.